

Novo Nordisk AS (NOVO B) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/N3848147CB3EN.html>

Date: February 2021

Pages: 69

Price: US\$ 125.00 (Single User License)

ID: N3848147CB3EN

Abstracts

Novo Nordisk AS (NOVO B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Novo Nordisk AS (Novo Nordisk), a subsidiary of Novo Holdings AS, is a healthcare company that discovers, develops and manufactures innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions including hemophilia, human growth hormone (HGH) disorders and obesity. The company's portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for hemophilia; glucagon; and oral antidiabetic agents. With subsidiaries in North America, Europe, Asia, Latin America, Africa, Middle East and Australia, the company markets its products in several countries worldwide. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

Novo Nordisk AS Key Recent Developments

Feb 03,2021: Novo Nordisk's net profit increased by 8% in 2020

Nov 09,2020: Novo Nordisk to acquire Emisphere Technologies for \$1.8bn

Oct 30,2020: Novo Nordisk's operating profit increased by 6% in Danish kroner and by 7% at constant exchange rates in the first nine months of 2020

Oct 13,2020: Alexander Mann Solutions partners with Novo Nordisk to support its global healthcare recruitment requirements

Oct 08,2020: Novo Nordisk raises sales and operating profit outlook for 2020

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

Table of Contents

List of Tables

List of Figures

SECTION 1 - ABOUT THE COMPANY

Novo Nordisk AS - Key Facts

Novo Nordisk AS - Key Employees

Novo Nordisk AS - Key Employee Biographies

Novo Nordisk AS - Major Products and Services

Novo Nordisk AS - History

Novo Nordisk AS - Company Statement

Novo Nordisk AS - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview

Novo Nordisk AS - Business Description

Business Segment: Biopharmaceuticals

Overview

Performance

Business Segment: Diabetes and Obesity Care

Overview

Performance

Key Stats

Geographical Segment: International Operations

Target Markets

Performance

Geographical Segment: North America

Target Markets

Performance

R&D Overview

Novo Nordisk AS - Corporate Strategy

Novo Nordisk AS - SWOT Analysis

SWOT Analysis - Overview

Novo Nordisk AS - Strengths
Novo Nordisk AS - Weaknesses
Novo Nordisk AS - Opportunities
Novo Nordisk AS - Threats
Novo Nordisk AS - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Novo Nordisk AS, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Feb 03, 2021: Novo Nordisk's net profit increased by 8% in 2020
Nov 09, 2020: Novo Nordisk to acquire Emisphere Technologies for \$1.8bn
Oct 30, 2020: Novo Nordisk's operating profit increased by 6% in Danish kroner and by 7% at constant exchange rates in the first nine months of 2020
Oct 13, 2020: Alexander Mann Solutions partners with Novo Nordisk to support its global healthcare recruitment requirements
Oct 08, 2020: Novo Nordisk raises sales and operating profit outlook for 2020
Sep 24, 2020: World's largest study of cardiovascular disease in type 2 diabetes shows need for improved knowledge and disease management
Sep 21, 2020: Novo Nordisk launches new 100% renewable power target for suppliers
Sep 10, 2020: ACC, Novo Nordisk partner to improve Cardiovascular Disease Management in patients with Type 2 Diabetes
Aug 18, 2020: Evotec and Novo Nordisk form strategic alliance to develop novel therapies for kidney diseases
Aug 14, 2020: Novo Nordisk invests DKK 850 million in production facilities in Kalundborg

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Novo Nordisk AS, Key Facts
Novo Nordisk AS, Key Employees
Novo Nordisk AS, Key Employee Biographies
Novo Nordisk AS, Major Products and Services
Novo Nordisk AS, History
Novo Nordisk AS, Subsidiaries
Novo Nordisk AS, Key Competitors
Novo Nordisk AS, Ratios based on current share price
Novo Nordisk AS, Annual Ratios
Novo Nordisk AS, Annual Ratios (Cont...1)
Novo Nordisk AS, Annual Ratios (Cont...2)
Novo Nordisk AS, Interim Ratios
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Novo Nordisk AS, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Novo Nordisk AS, Performance Chart (2016 - 2020)

Novo Nordisk AS, Ratio Charts

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

COMPANIES MENTIONED

Teva Pharmaceutical Industries Ltd

Takeda Pharmaceutical Co Ltd

Takeda Pharma AS

Sanofi

Pfizer Inc

Orifarm Group A/S

Orexigen Therapeutics Inc

Novartis AG

Merck & Co Inc

Johnson & Johnson

H. Lundbeck AS

GlaxoSmithKline Plc

Flowsion A/S

F. Hoffmann-La Roche Ltd

Eli Lilly and Co

Dansk Biotek

Bristol-Myers Squibb Co

Billev Pharma ApS

AstraZeneca Plc

Arrow Pharma ApS

ALK-Abello AS

I would like to order

Product name: Novo Nordisk AS (NOVO B) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/N3848147CB3EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N3848147CB3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970